Top-performing Mass. biotech Corbus extends study of promising drug
Norwood-based Corbus Pharmaceuticals, the top-performing biotech stock in the state so far in 2016, said Tuesday that it will extend a Phase 2 study of its only drug in development.
Corbus (Nasdaq: CRBP) said that the FDA had approved a one-year, open-label extension study of the trial of anti-inflammatory drug Resunab to treat skin-predominant dermatomyositis. In April, the regulator approved a one-year extension study of Resunab for patients with systemic sclerosis. The com pany said in a statement…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Max Stendahl Source Type: news
More News: Biotechnology | Dermatology | Dermatomyositis | Health Management | Pharmaceuticals | Scleroderma | Skin | Study